Clinical Trials Logo

Filter by:
NCT ID: NCT06191484 Recruiting - Suicide Clinical Trials

Risk and Resilience to Suicide Following Late-Life Spousal Bereavement

RISE
Start date: November 20, 2023
Phase: N/A
Study type: Interventional

The purpose of the RISE study is to examine how the 24-hour rhythm of sleep and social activity relate to mood and suicidal ideation among older adults that recently lost a spouse or life partner.

NCT ID: NCT06191419 Recruiting - Tobacco Smoking Clinical Trials

Human Perception of Odors and Odor Blockers

Start date: April 5, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to determine whether blockers of perception of key odorants in cigarette smoke have any utility in smoking cessation. The main question it aims to answer is: • Can odor blockers be used to suppress perception of the intensity of cigarette smoke in ways that reduce the ability of the odor of cigarette smoke to increase the urge to smoke. Participants will be asked to smell up to 20 odor samples per session and report on odor pleasantness and desire to smoke.

NCT ID: NCT06191393 Recruiting - Clinical trials for SARS-CoV-2 Infection

SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings

Start date: November 20, 2023
Phase: N/A
Study type: Interventional

The Metrix COVID/Flu Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein. The study will take place in simulated home environments which will be set up within or near active clinical settings (e.g., urgent care facilities). This will be a prospective study conducted at three or more investigational sites located within the United States for the clinical validation of the Metrix COVID/Flu Test for the differential detection of SARS-CoV-2, Influenza A, and Influenza B in AN swab or saliva samples. Additional sites may be added to the study in order to meet minimum subject/sample enrollment requirements and geographic prevalence of respiratory virus infections. One or more investigational sites outside of the US (at which participants are required to be fluent in English) may also be included in the study depending on enrollment needs and geographical/seasonal prevalence of respiratory virus infections. Comparator testing will be performed to determine the infection status of each sample for comparison to results generated by the candidate test. The primary comparator for the study will be an FDA-cleared assay for the detection of SARS-CoV-2, Flu A, and/or Flu B.

NCT ID: NCT06191380 Recruiting - Multiple Sclerosis Clinical Trials

Effects of Cycling and Virtual Reality on Thinking Speed in Persons With MS (PACE-MS)

PACE-MS
Start date: February 12, 2024
Phase: N/A
Study type: Interventional

To compare the effects of cycling exercise with different types of virtual reality on processing/thinking speed in persons with multiple sclerosis (MS).

NCT ID: NCT06191315 Recruiting - Asthma Clinical Trials

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

Start date: January 3, 2024
Phase: Phase 3
Study type: Interventional

This is a parallel, Phase 3, 2-arm study to evaluate the efficacy and long-term safety of dupilumab treatment in children 2 to <6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted in 2 parts. Part A will be a 52-week, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of dupilumab in children aged 2 to <6 years old with uncontrolled asthma and/or recurrent severe asthmatic wheeze. At the end of Part A, all eligible participants will be offered participation in Part B, an optional open-label extension phase. Study details include: Part A: The study duration of part A will be up to 68 weeks consisting of a 4-week Screening, a 52week treatment period, and a 12-week post-treatment follow-up period. For participants who will chose to participate in Part B, the study duration will be up to 120 weeks (additional 52-week treatment period). Part B: For participants who will choose to participate in Part B, the study duration will be up to 120 weeks (Part A [4-week Screening and a 52-week treatment period] plus additional 52-week treatment period and a 12-week post-treatment follow-up period).

NCT ID: NCT06191289 Recruiting - Suicide Clinical Trials

Neurocognitive Mechanisms of Perimenstrual Estrogen Effects on Suicidality

CLEAR-4
Start date: March 16, 2024
Phase: Phase 2
Study type: Interventional

This within-person, crossover, 2-condition, placebo-controlled study compares the impact of two perimenstrual conditions on severity of suicidal symptoms in females with past-month suicidality but minimal risk of imminent suicide attempt. The two conditions are (1) perimenstrual administration of estradiol and (2) natural perimenstrual withdrawal from estradiol during placebo.

NCT ID: NCT06191198 Not yet recruiting - Clinical trials for Primary Progressive Aphasia

Communication Bridge 3 Study

CB3
Start date: July 15, 2024
Phase: Phase 2
Study type: Interventional

This study will use a randomized controlled trial design to evaluate the effect of two evidence-based treatments for adults with mild-moderate Primary Progressive Aphasia (PPA). The aim of the study is to help us better understand the effects of speech-language therapy on communication abilities in individuals with PPA.

NCT ID: NCT06191185 Not yet recruiting - Colorectal Cancer Clinical Trials

IMProving Adherence to Colonoscopy Through Teams and Technology

IMPACTT
Start date: April 2024
Phase: N/A
Study type: Interventional

Complete and timely colonoscopy after an abnormal stool-based colorectal cancer screening test results in early detection, cancer prevention, and reduction in mortality, but follow-up in safety-net health systems occurs in less than 50% at 6 months. The proposal will implement multi-level approach consisting of a stepped-wedge clinic-level intervention of team-based best practices co-developed with primary and specialty care, a patient-level technology intervention to provide enhanced instructions and navigation to complete diagnostic colonoscopy, and a mixed methods evaluation to explore multi-level factors contributing to intervention outcomes. Developing a solution to this high-risk and diverse population has the potential to translate to other health systems, support patient self-management, and address other patient conditions.

NCT ID: NCT06190912 Recruiting - Multiple Sclerosis Clinical Trials

Safety of Bryostatin in Patients With MS

Start date: April 11, 2024
Phase: Phase 1
Study type: Interventional

This is a single-site, single-arm, single-dose, Phase 1 study of the safety of bryostatin in participants with multiple sclerosis (MS) receiving any disease modifying therapy (DMT).

NCT ID: NCT06190899 Recruiting - Prostate Cancer Clinical Trials

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Start date: January 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combination with darolutamide in subjects with mCRPC.